Skip to main content
Clinical Trials/NCT02311816
NCT02311816
Completed
Not Applicable

Increase in Procalcitonin Kinetics May be a Good Indicator of Starting Empirical Antibiotic Treatment in Critically Ill Patients

Domonkos Trásy1 site in 1 country114 target enrollmentOctober 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bacterial Infection
Sponsor
Domonkos Trásy
Enrollment
114
Locations
1
Primary Endpoint
Procalcitonin kinetic
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The value of procalcitonin change from the day before to the day when infection was suspected in predicting bacterial infection in intensive care patients.

Detailed Description

Starting antibiotic therapy early in critically ill patients with suspected infection is of utmost importance with significant effect on survival. Procalcitonin is a reliable sepsis marker but results about its usefulness in initiating antimicrobials are conflicting. Our aim is to investigate the predictive value of 24 hours procalcitonin kinetics before starting empirical antibiotic therapy in intensive care patients as an indicator of the presence of bacterial infection.

Registry
clinicaltrials.gov
Start Date
October 2012
End Date
October 2013
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Domonkos Trásy
Responsible Party
Sponsor Investigator
Principal Investigator

Domonkos Trásy

Ph.D. student; Department of Anaesthesiology and Intensive Therapy

Szeged University

Eligibility Criteria

Inclusion Criteria

  • Clinical signs of infection
  • Suspected or proven acute infection requiring empiric antibiotic therapy as decided by the attending ICU physician
  • Microbiological sample sent for staining
  • Inflammatory markers available from the previous day

Exclusion Criteria

  • Patients younger than 18 years
  • Who received prophylactic or empiric antibiotic therapy 48 hours before inclusion
  • Whose receiving acute renal replacement therapy in the first 24 hours following antibiotic treatment
  • Following cardiopulmonary resuscitation
  • End stage diseases with a "do not resuscitate" order
  • Immunocompromised patients (human immunodeficiency virus infection, bone marrow transplantation, malignant haematological disorders and chemotherapy)
  • Post cardiac surgery patients

Outcomes

Primary Outcomes

Procalcitonin kinetic

Time Frame: 24 hours before starting empiric antibiotic treatment

Procalcitonin levels are measured at starting empiric antibiotic treatment and 24 hours before. The changes in percentage are calculated form the day before and right before the first exposition of the antibiotic therapy.

Secondary Outcomes

  • White blood cell count kinetic(24 hours before starting empiric antibiotic treatment)
  • Body temperature kinetic(24 hours before starting empiric antibiotic treatment)
  • C-reactive protein kinetic(24 hours before starting empiric antibiotic treatment)

Study Sites (1)

Loading locations...

Similar Trials